|
Q4 FY2025
As of Dec 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
|
|---|---|---|---|---|---|---|---|---|---|
| CURRENT ASSETS: | |||||||||
| Cash and cash equivalents | |||||||||
| Restricted deposits | |||||||||
| Short-term bank deposits | |||||||||
| Trade receivables, net | |||||||||
| Inventories | |||||||||
| Other receivables | |||||||||
| Total current assets | |||||||||
| LONG-TERM ASSETS: | |||||||||
| Other receivables | |||||||||
| Long-term restricted bank deposits | |||||||||
| Property, plant and equipment | |||||||||
| Right-of-use assets | |||||||||
| Intangible assets | |||||||||
| Total non-current assets | |||||||||
| Total assets | |||||||||
| Current liabilities | |||||||||
| Current maturities of long-term liabilities | |||||||||
| Warrants | |||||||||
| Trade payables and accrued expenses | |||||||||
| Other payables | |||||||||
| Total current liabilities | |||||||||
| Non-current liabilities | |||||||||
| Warrants, net | |||||||||
| Grants received in advance | |||||||||
| Liabilities in respect of IIA grants | |||||||||
| Liabilities in respect of TEVA | |||||||||
| Lease liabilities | |||||||||
| Severance pay liability, net | |||||||||
| Total non-current liabilities | |||||||||
| Total liabilities | |||||||||
| Shareholders' equity: | |||||||||
| Ordinary shares of NIS 0.07 par value: Authorized 20,000,000 shares as of December 31, 2025 and 2024; Issued and Outstanding 12,835,185 shares as of December 31, 2025 and 10,793,057 shares as of December 31, 2024 | |||||||||
| Share premium | |||||||||
| Foreign currency translation reserve | |||||||||
| Accumulated deficit | |||||||||
| Total equity | |||||||||
| Total liabilities and equity | |||||||||
Loading...
